Literature DB >> 6736447

Clinical failure of streptokinase due to an unsuspected high titer of antistreptokinase antibody.

A S Lew, T Neer, L Rodriguez, I L Geft, P K Shah, W Ganz.   

Abstract

Neutralization of streptokinase by an unsuspected high titer of antistreptokinase antibody prevented activation of the fibrinolytic system and induction of a lytic state in a 62 year old man with an acute inferior myocardial infarction. There was no decrease in serum fibrinogen, minimal decrease in serum plasminogen and only a small increase in serum fibrin degradation products after intravenous administration of 1.5 million units of streptokinase. A high titer of antistreptokinase antibody, sufficient to neutralize 1.5 million units of streptokinase, was demonstrated by semiquantitative counterelectrophoresis . There was no clinical evidence of coronary artery reperfusion, and coronary angiography confirmed complete occlusion of the left circumflex artery.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6736447     DOI: 10.1016/s0735-1097(84)80339-3

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  9 in total

Review 1.  Is the development of antibodies to streptokinase clinically relevant?

Authors:  M B Buchalter
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

2.  Consequences of antibody binding in vitro on the pharmacological properties of anisoylated plasminogen streptokinase activator complex.

Authors:  R Fears; H Ferres; M Hibbs; R Standring
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 3.  Does the potential for development of streptokinase antibodies change the risk-benefit ratio in older patients?

Authors:  J Brügemann; P A de Graeff; J van der Meer; K I Lie
Journal:  Drugs Aging       Date:  1995-08       Impact factor: 3.923

4.  Streptokinase antibodies are of clinical importance and they can be measured in half an hour by a simple enzyme-linked immunosorbent assay.

Authors:  J Brügemann; J van der Meer; V J Bom; K I Lie
Journal:  Br Heart J       Date:  1994-08

Review 5.  Adverse reactions to thrombolytic agents. Implications for coronary reperfusion following myocardial infarction.

Authors:  J Nazari; R Davison; K Kaplan; D Fintel
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Jul-Aug

6.  Pre-dosing antibody levels and efficacy of thrombolytic drugs containing streptokinase.

Authors:  J D Gemmill; K J Hogg; F G Dunn; A P Rae; W S Hillis
Journal:  Br Heart J       Date:  1994-09

Review 7.  Streptokinase. A review of its pharmacology and therapeutic efficacy in acute myocardial infarction in older patients.

Authors:  P E Battershill; P Benfield; K L Goa
Journal:  Drugs Aging       Date:  1994-01       Impact factor: 3.923

Review 8.  Engineered microparticles and nanoparticles for fibrinolysis.

Authors:  Dante Disharoon; David W M Marr; Keith B Neeves
Journal:  J Thromb Haemost       Date:  2019-10-07       Impact factor: 5.824

9.  The significance of anti-streptokinase antibodies.

Authors:  M Lynch; B L Pentecost; W A Littler; R A Stockley
Journal:  Clin Exp Immunol       Date:  1994-06       Impact factor: 4.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.